Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate

By Richard Eastell, I. Barton, R. Hannon, A. Chines, P. Garnero, P. Delmas. Journal of Bone and Mineral Research, 2003

607 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Orthopedics and Sports Medicine

View Paper: https://www.semanticscholar.org/paper/3e09e2eb0164c53f2fa0390923a044bdf190d9c7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

In Orthopedics and Sports Medicine

Citations in the corpus

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards (2011, methodology): “In the VERT study, the change in u-CTX and u-NTX at 3 to 6 months explained between 54% and 77% of the fracture risk reduction with risedronate, depending on the marker, the method of analysis and the fracture type [123].”
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. (2006, background): “Decreased bone turnover has been associated with decreased fracture risk independent of BMD effects,(33,34) and among women treated for osteoporosis, greater reductions in turnover are associated with fewer fractures.(35,36) Potential mechanisms include allowing resorption pits to fill with bone and”
European guidance for the diagnosis and management of osteoporosis in postmenopausal women (2008, background): “More importantly, significant associations have been reported between the short-term decrease in markers of bone turnover and the reduction in risk of vertebral and nonvertebral fractures with the use of antiresorptive agents (raloxifene and bisphosphonates) [74, 272–276].”
Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. (2019, background): “In women, a low risk of fractures while on treatment is associated with BTMs that are below themedian of the reference interval for youngwomen (166).”
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy (2008, background): “The clinical relevance of these differences is unclear; it has been shown that reductions in serum CTX of greater than 50% from baseline values may not provide further fracture reduction [153, 154].”
Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. (2006, background): “Indeed, it may be unnecessary to suppress to more than premenopausal levels in order to achieve maximal fracture reduction [75].”